Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.
P/B ratio for Aethlon Medical, Inc. (AEMD)
P/B ratio as of 2024: 0.75
According to Aethlon Medical, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.75. At the end of 2023 the company had a P/B ratio of 0.52.
P/B ratio history for Aethlon Medical, Inc. from 1997 to 2024
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2024 | 0.75 |
| 2023 | 0.52 |
| 2022 | 1.26 |
| 2021 | 2.60 |
| 2020 | 0.55 |
| 2019 | 6.65 |
| 2018 | 2.39 |
| 2017 | 37.54 |
| 2016 | 25.52 |
| 2015 | 104.53 |
| 2014 | -2.47 |
| 2013 | -1.79 |
| 2012 | -10.95 |
| 2011 | -13.98 |
| 2010 | -48.87 |
| 2009 | -20.66 |
| 2008 | -54.87 |
| 2007 | -28.11 |
| 2006 | -90.01 |
| 2005 | -15.10 |
| 2004 | -30.22 |
| 2003 | -7.66 |
| 2002 | -34.07 |
| 2001 | -28.19 |
| 2000 | -329.71 |
| 1999 | -181.79 |
| 1998 | -88365.31 |
| 1997 | 45597.09 |